Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) EBITDA Margin (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed EBITDA Margin for 3 consecutive years, with 188.49% as the latest value for Q1 2025.

  • On a quarterly basis, EBITDA Margin changed N/A to 188.49% in Q1 2025 year-over-year; TTM through Sep 2025 was 1614.62%, a 783832.0% decrease, with the full-year FY2023 number at 2161.02%, changed N/A from a year prior.
  • EBITDA Margin was 188.49% for Q1 2025 at Centessa Pharmaceuticals, down from 1405.56% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 3979.73% in Q2 2022 to a low of 188.49% in Q1 2025.
  • A 3-year average of 2029.46% and a median of 1951.63% in 2022 define the central range for EBITDA Margin.
  • Biggest YoY gain for EBITDA Margin was -54607bps in 2023; the steepest drop was -302704bps in 2023.
  • Centessa Pharmaceuticals' EBITDA Margin stood at 1951.63% in 2022, then fell by -28bps to 1405.56% in 2023, then plummeted by -113bps to 188.49% in 2025.
  • Per Business Quant, the three most recent readings for CNTA's EBITDA Margin are 188.49% (Q1 2025), 1405.56% (Q4 2023), and 1527.55% (Q3 2023).